This article is more than 9 years old.
This puts Imbruvica among the best launches for a blood cancer drug ever, better than blockbusters like Celgene's Revlimid and Novartis' Gleevec. Part of the reason is that cancer drugs are, generally more expensive than they used to be. And drug launches don't always translate into later success-- or else Viagra would have been the best-selling drug ever. But this is definitely good news for Pharmacyclics and its investors, and a sign that Imbruvica is really on its way to being a big drug. The graph above comes from an analyst report by Howard Liang at Leerink.